In-vitro dissolution testing of 5-aminosalicylic acid release from pH dependent mesalazine formulations

被引：0
|
作者：
Kruis, Wolfgang [2 ]
Greinwald, Roland [1 ]
Fingerhut, Thomas [3 ]
机构：
[1] Dr Falk Pharma GmbH, Res & Dev, Freiburg, Germany
[2] Univ Cologne, Evangel Krankenhaus Kalk, Cologne, Germany
[3] Dr Falk Pharma GmbH, Qual Assurance & Qual Control, Freiburg, Germany
来源：
JOURNAL OF CROHNS & COLITIS | 2011年 / 5卷 / 05期
关键词：
ACTIVE ULCERATIVE-COLITIS; DOUBLE-BLIND; PELLETS; TABLETS; TRIAL;
D O I：
10.1016/j.crohns.2011.04.003
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：499 / 500
页数：2
相关论文
共 50 条
  • [11] What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
    Riley, SA
    GUT, 1998, 42 (06) : 761 - 763
  • [12] Release kinetics of 5-aminosalicylic acid from halloysite
    Aguzzi, C.
    Viseras, C.
    Cerezo, P.
    Salcedo, I.
    Sanchez-Espejo, R.
    Valenzuela, C.
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2013, 105 : 75 - 80
  • [13] In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness
    Tenjarla, Srini
    Abinusawa, Adeyinka
    ADVANCES IN THERAPY, 2011, 28 (01) : 62 - 72
  • [14] Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): An open trial
    Dekker-Saeys, BJ
    Dijkmans, BAC
    Tytgat, GNJ
    JOURNAL OF RHEUMATOLOGY, 2000, 27 (03) : 723 - 726
  • [15] In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness
    Srini Tenjarla
    Adeyinka Abinusawa
    Advances in Therapy, 2011, 28 : 62 - 72
  • [16] 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers
    Brunner, M
    Lackner, E
    Exler, PS
    De Fluiter, HC
    Kletter, K
    Tschurlovits, M
    Dudczak, R
    Eichler, HG
    Müller, M
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (01) : 137 - 144
  • [17] Synthesis, characterization and in vitro release of 5-aminosalicylic acid and 5-acetyl aminosalicylic acid of polyanhydride - P(CBFAS)
    Cai, QX
    Zhu, KJ
    Chen, D
    Gao, LP
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 55 (02) : 203 - 208
  • [18] HIGH SERUM AND URINARY LEVELS OF FREE 5-AMINOSALICYLIC ACID (TOXIC FORM) IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE MAINTAINED ON PH DEPENDENT RELEASE MESALAZINE
    MAHMUD, N
    WEIR, DG
    KELLEHER, D
    GASTROENTEROLOGY, 1995, 108 (04) : A869 - A869
  • [19] BIOAVAILABILITY OF 5-AMINOSALICYLIC ACID FROM SLOW-RELEASE 5-AMINOSALICYLIC ACID DRUG AND SULFASALAZINE IN NORMAL-CHILDREN
    CHRISTENSEN, LA
    FALLINGBORG, J
    JACOBSEN, BA
    ABILDGAARD, K
    RASMUSSEN, HH
    RASMUSSEN, SN
    HANSEN, SH
    DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (10) : 1831 - 1836
  • [20] Cytotoxicity of mesalazine (5-aminosalicylic acid) and related compounds in different cell lines
    Dierick, PJ
    Janssen, L
    Noble, E
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R429 - R429
12345